SNDX
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals Inc (SNDX) has 6 SEC Form 4 filings (10 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: Jul 9, 2026.
The most active filer is Chief Executive Officer Metzger Michael A with 3 filings. Insiders have net sold $2.6M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Michael A. Metzger
- Employees:270
- HQ:New York City, NY, US
- IPO:2016-03-02
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.6M
reported sales (SEC code S)
Unique Insiders
3
in the rolling window
Market Cap
$1.8B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Executive Officer | Sale | 32,375 | $785K | Jul 9 | SEC ↗ | |
Botwood Nicholas A.J.First filing | Head of R&D, CMO | Sale | 34,280 | $617K | Jun 12 | SEC ↗ |
Botwood Nicholas A.J.First filing | Head of R&D, CMO | Sale | 31,235 | $567K | Jun 12 | SEC ↗ |
Metzger Michael AFirst in 4 months | Chief Executive Officer | Sale | 6,847 | $130K | Jun 2 | SEC ↗ |
Goldan Keith A.First in 4 months | Chief Financial Officer | Sale | 1,177 | $22K | Jun 2 | SEC ↗ |
Goldan Keith A.First filing | Chief Financial Officer | Sale | 3,410 | $72K | Feb 10 | SEC ↗ |
Metzger Michael AFirst filing | Chief Executive Officer | Sale | 17,159 | $361K | Feb 10 | SEC ↗ |
Related companies
Syndax Pharmaceuticals Inc is in the Healthcare sector.